Trials / Completed
CompletedNCT00380575
Study of IV YM087 to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia
A 4-Day, Double-Blind, Placebo-Controlled, Multicenter Study of IV YM087 (CI-1025) to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 84 (planned)
- Sponsor
- Cumberland Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will investigate the application of a vasopressin antagonist in the treatment of hyponatremia most likely caused by inappropriate AVP secretion. The population studied will include patients with euvolemic or hypervolemic hyponatremia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | YM087 |
Timeline
- Start date
- 2000-08-01
- Completion
- 2003-02-01
- First posted
- 2006-09-26
- Last updated
- 2014-05-02
Locations
47 sites across 4 countries: United States, Canada, Israel, South Africa
Source: ClinicalTrials.gov record NCT00380575. Inclusion in this directory is not an endorsement.